SAN DIEGO, July 23 /EMWNews/ -- Anadys Pharmaceuticals,

Inc. (Nasdaq: ANDS) announced today that it will report second quarter 2008

financial results on Wednesday, July 30, 2008, after the U.S. financial

markets close.



    Anadys will hold a conference call and webcast to discuss its second

quarter 2008 financial results and highlights and to provide an update on

its development programs on Wednesday, July 30, 2008 at 5:00 p.m. Eastern

Daylight Time. A live webcast of the call will be available online at

http://www.anadyspharma.com. A telephone replay will also be available

approximately one hour after completion of the call. To access the

telephone replay, dial 888-286-8010 (domestic) or 617-801-6888

(international), passcode 79911148. The webcast and telephone replay will

be available through August 13, 2008.

    About Anadys



    Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical

company dedicated to improving patient care by developing novel medicines

in the areas of hepatitis C and oncology. For the treatment of chronic

hepatitis C, the Company is developing ANA598, a non-nucleoside polymerase

inhibitor, and ANA773, an oral TLR7 agonist prodrug. The Company is also

developing ANA773 for the treatment of cancer.



    Safe Harbor Statement



    Statements in this press release that are not strictly historical in

nature constitute "forward-looking statements." Such statements include,

but are not limited to, references to Anadys' strategy, development

programs, and ability to develop novel medicines in the areas of hepatitis

C and oncology. Such forward-looking statements involve known and unknown

risks, uncertainties and other factors, which may cause Anadys' actual

results to be materially different from historical results or from any

results expressed or implied by such forward-looking statements. For

example, the results of preclinical studies may not be predictive of future

results, and Anadys cannot provide any assurances that ANA598 and ANA773

will not have unforeseen safety issues, will have favorable results in

future clinical trials or will receive regulatory approval. Risk factors

that may cause actual results to differ are discussed in Anadys' SEC

filings, including Anadys' Form 10-K for the year ended December 31, 2007

and Anadys' Form 10-Q for the quarter ended March 31, 2008. All

forward-looking statements are qualified in their entirety by this

cautionary statement. Anadys is providing this information as of this date

and does not undertake any obligation to update any forward-looking

statements contained in this document as a result of new information,

future events or otherwise.